Potentially fatal complications of new systemic anticancer therapies: pearls and pitfalls in their initial management

Kovac, Milena Blaz; Seruga, Bostjan

doi:10.2478/raon-2024-0027

References

Bischof JJ, Presley CJ, Caterino JM. Addressing new diagnostic and treatment challenges associated with a new age of cancer treatment. Ann Emerg Med 2019; 73: 88–90. doi: 10.1016/j.annemergmed.2018.08.421
Open DOI Search in Google Scholar Back to article
Mayer DK, Travers D, Wyss A, Leak A, Waller A. Why do patients with cancer visit emergency departments? Results of a 2008 population study in North Carolina. J Clin Oncol 2011; 29: 2683–8. doi: 10.1200/JCO.2010.34.2816
Open DOI Search in Google Scholar Back to article
Lewis MA, Hendrickson WA, Moynihan TJ. Oncologic emergencies: pathophysiology, presentation, diagnosis, and treatment. CA Cancer J Clin 2011; 61: 287–314. doi: 10.3322/caac.20124
Open DOI Search in Google Scholar Back to article
Alahmadi A, Altamimi H, Algarni M. Evaluation of knowledge of immunotherapy toxicities among emergency physicians in Riyadh, Saudi Arabia. Cureus 2022; 14: e30325. doi: 10.7759/cureus.30325
Open DOI Search in Google Scholar Back to article
Higdon ML, Higdon JA. Treatment of oncologic emergencies. Am Fam Physician 2006; 74: 1873–80. PMID: 17168344
Search in Google Scholar Back to article
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252–64. doi: 10.1038/nrc3239
Open DOI Search in Google Scholar Back to article
Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27: 559–74. doi: 10.1093/annonc/mdv623
Open DOI Search in Google Scholar Back to article
Palaskas N, Lopez-Mattei J, Durand JB, et al. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc 2020; 9: e013757. doi: 10.1161/JAHA.119.013757
Open DOI Search in Google Scholar Back to article
Müller-Jensen L, Zierold S, Versluis JM, Boehmerle W, Huehnchen P, Matthias Endres M, et al. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: a retrospective multicentre cohort study. Eur J Cancer 2022; 175: 224–35. doi: 10.1016/j.ejca.2022.08.009
Open DOI Search in Google Scholar Back to article
Haanen J, Obeid N, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33: 1217–38. doi: 10.1016/j.annonc.2022.10.001
Open DOI Search in Google Scholar Back to article
Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013; 10: 267–76. doi: 10.1038/nrclinonc.2013.46
Open DOI Search in Google Scholar Back to article
Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol 2021; 18: 71–84. doi: 10.1038/s41571-020-0427-6
Open DOI Search in Google Scholar Back to article
Kish J, Liu R, Pfeffer D, Vennam S, Lussier C, Nayak P. Real-world duration of hospitalization for CAR-T treatment: U.S. patient experience in multiple hematologic malignancies. [abstract]. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). J Clin Oncol 2023; 41(Suppl S): e18896. doi: Goebeler ME, Bargou RC. T cell-engaging therapies - BiTEs and beyond. Nat Rev Clin Oncol 2020; 17: 418–34. doi: 10.1038/s41571-020-0347-5
Open DOI Search in Google Scholar Back to article
Ball K, Dovedi SJ, Vajjah P, Phipps A. Strategies for clinical dose optimization of T cell-engaging therapies in oncology. mAbs 2023; 15: 2181016. doi: 10.1080/19420862.2023.2181016
Open DOI Search in Google Scholar Back to article
Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med 2020; 383: 2255–73. doi: 10.1056/NEJMra2026131
Open DOI Search in Google Scholar Back to article
Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019; 25: 625–38. doi: 10.1016/j.bbmt.2018.12.758
Open DOI Search in Google Scholar Back to article
Hernani R, Benzaquén A, Solan C. Toxicities following CAR-T therapy for hematological malignancies. Cancer Treat Rev 2022: 111: 102479. doi: 10.1016/j.ctrv.2022.102479
Open DOI Search in Google Scholar Back to article
Morris EM, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 2022; 22: 85–96. doi: 10.1038/s41577-021-00547-6
Open DOI Search in Google Scholar Back to article
Rejeski K, Subklewe M, Locke FL. Recognizing, defining, and managing CAR-T hematologic toxicities. Hematology Am Soc Hematol Educ Program 2023; 2023: 198–208. doi: 10.1182/hematology.2023000472
Open DOI Search in Google Scholar Back to article
Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 2018; 15: 47–62. doi: 10.1038/nrclinonc.2017.148.
Open DOI Search in Google Scholar Back to article
Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO Guideline. J Clin Oncol 2021; 39: 3978–92. doi: 10.1200/JCO.21.01992
Open DOI Search in Google Scholar Back to article
Strati P, Ahmed S, Kebriaei P, Nastoupil LJ, Claussen CM, Watson G, et al. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv 2020; 4: 3123–7. doi: 10.1182/bloodadvances.2020002328
Open DOI Search in Google Scholar Back to article
Rosée PL, Horne AC, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 2019; 133: 2465–77. doi: 10.1182/blood.2018894618
Open DOI Search in Google Scholar Back to article
Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol 2021; 18: 327–44. doi: 10.1038/s41571-021-00470-8
Open DOI Search in Google Scholar Back to article
Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol 2024; 21: 203–23. doi: 10.1038/s41571-023-00850-2
Open DOI Search in Google Scholar Back to article
Tarantino P, Ricciuti B, Pradhan SM. Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat Rev Clin Oncol 2023; 20: 558–76. doi: 10.1038/s41571-023-00783-w
Open DOI Search in Google Scholar Back to article
Rugo HS, Crossno CL, Gesthalter YB, Kelley K, Moore HB, Rimawi MF, et al. Real-world perspectives and practices for pneumonitis/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2-expressing metastatic breast cancer. JCO Oncol Pract 2023; 19: 539–46. doi: 10.1200/OP.22.00480
Open DOI Search in Google Scholar Back to article
Lacouture ME, Patel AB, Rosenberg JE, Peter H O’Donnell. Management of dermatologic events associated with the nectin-4-directed antibody-drug conjugate enfortumab vedotin. Oncologist 2022; 27: e223–32. doi: 10.1093/oncolo/oyac001
Open DOI Search in Google Scholar Back to article
Cooksley T, Rice T. Emergency oncology: development, current position and future direction in the USA and UK. Support Care Cancer 2017; 25: 3–7. doi: 10.1007/s00520-016-3470-1
Open DOI Search in Google Scholar Back to article

Potentially fatal complications of new systemic anticancer therapies: pearls and pitfalls in their initial management

References

Paradigm

My account